SCHEMBL25833239

SCHEMBL25833239

CCCCC(CCC)CCC(=O)N1CCC2(CC1)CN(CC(CCCC)CCCC)C2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 5/20 0.37
OPRM1 P35372 2/20 0.37
CHRM2 P08172 1/20 0.37
HTR1A P08908 1/20 0.37
ADRA2A P08913 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
CHRM1 P11229 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
DRD3 P35462 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KCNH2 Q12809 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ITGB3 P05106 3/20 0.36
ITGA2B P08514 3/20 0.36
TSHR P16473 2/20 0.36
PDE3B Q13370 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24673510 1.00 CYP2D6 (0.37) CYP2D6OPRM1CHRM2HTR1AADRA2A
SCHEMBL25707248 0.98 L3MBTL1 (0.38) CYP2D6OPRM1CHRM2HTR1AADRA2A
SCHEMBL25730291 0.95 L3MBTL1 (0.40) CYP2D6OPRM1CHRM2HTR1AADRA2A
SCHEMBL26408556 0.94 L3MBTL1 (0.39) CYP2D6OPRM1CHRM2HTR1AADRA2A
SCHEMBL23945974 0.94 L3MBTL1 (0.39) CYP2D6OPRM1CHRM2HTR1AADRA2A
SCHEMBL25923583 0.90 CYP2D6 (0.38) CYP2D6OPRM1CHRM2HTR1AADRA2A
SCHEMBL25707305 0.86 CA2 (0.41) CYP2D6OPRM1CHRM2HTR1AADRA2A
SCHEMBL23945726 0.86 CYP2D6 (0.37) CYP2D6OPRM1CHRM2HTR1AADRA2A
SCHEMBL25927258 0.85 CYP2D6 (0.46) CYP2D6L3MBTL1MEN1KMT2ATDP1
SCHEMBL25887917 0.84 L3MBTL1 (0.38) CYP2D6L3MBTL1MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CYP2D6 3599/4885OPRM1 4472/4885CHRM2 4681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.